Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Milestone Pharmaceuticals Inc.MIST · Entity 6561 | Director | July 11, 2025 | July 15, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Milestone Pharmaceuticals Inc.
Report date July 11, 2025 · Filed July 15, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 16,793 |
Reported balance
After 2025-07-11 transaction · row 1
1 source rowRow 1 · 2025-07-11 · Grant · Acquired 16,666 · Balance 16,793 F1: The reported securities are included within 16,793 Issuer Units purchased by the Reporting Person for $1.50 per Unit. Each Unit consists of one common share, one Series A common warrant and one Series B common warrant, each warrant represents the right to purchase 16,793 shares of common stock. |
| Series A Common Warrants (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.50 · Expires 2026-07-11 | Direct | 16,793 |
Reported balance
After 2025-07-11 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-07-11 · Grant · Acquired 16,793 · Balance 16,793 F1: The reported securities are included within 16,793 Issuer Units purchased by the Reporting Person for $1.50 per Unit. Each Unit consists of one common share, one Series A common warrant and one Series B common warrant, each warrant represents the right to purchase 16,793 shares of common stock. F3: Fully vested and exercisable. |
| Series B Common Warrants (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.88 · Expires 2030-07-11 | Direct | 16,793 |
Reported balance
After 2025-07-11 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-07-11 · Grant · Acquired 16,793 · Balance 16,793 F1: The reported securities are included within 16,793 Issuer Units purchased by the Reporting Person for $1.50 per Unit. Each Unit consists of one common share, one Series A common warrant and one Series B common warrant, each warrant represents the right to purchase 16,793 shares of common stock. F3: Fully vested and exercisable. |
| Common SharesSEC Table I · non-derivative | IndirectBy: The Rodriguez and Liebert Revocable Trust | 10,000 |
Reported balance
Holding disclosure · report date 2025-07-11 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 10,000 |
| Common SharesSEC Table I · non-derivative | IndirectBy: Trust | 4,000 |
Reported balance
Holding disclosure · report date 2025-07-11 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 4,000 F2: These shares are held in a trust for the benefit of several including the Reporting Person's spouse. The Reporting Person's spouse is a co-executor of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities are included within 16,793 Issuer Units purchased by the Reporting Person for $1.50 per Unit. Each Unit consists of one common share, one Series A common warrant and one Series B common warrant, each warrant represents the right to purchase 16,793 shares of common stock.
F2: These shares are held in a trust for the benefit of several including the Reporting Person's spouse. The Reporting Person's spouse is a co-executor of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
F3: Fully vested and exercisable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 11, 2025 Filed Jul 15, 2025 20:15 UTC | Milestone Pharmaceuticals Inc. MIST · Entity 6561 | GrantSeries B Common Warrants (right to buy) · Derivative | 16,793 | Not disclosed Strike: $1.88 | Not disclosed |
DisclosureSEC source: 0001415889-25-019776 · form4-07152025_040723.xml · derivative · entry 5 Liebert Debra K. · CIK 0001772891 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,793 Underlying: Common Shares · 16,793 shares Expires 2030-07-11 F1 · price: The reported securities are included within 16,793 Issuer Units purchased by the Reporting Person for $1.50 per Unit. Each Unit consists of one common share, one Series A common warrant and one Series B common warrant, each warrant represents the right to purchase 16,793 shares of common stock. F3 · derivative.exercise_date: Fully vested and exercisable. Read SEC document |
| July 11, 2025 Filed Jul 15, 2025 20:15 UTC | Milestone Pharmaceuticals Inc. MIST · Entity 6561 | GrantSeries A Common Warrants (right to buy) · Derivative | 16,793 | Not disclosed Strike: $1.50 | Not disclosed |
DisclosureSEC source: 0001415889-25-019776 · form4-07152025_040723.xml · derivative · entry 4 Liebert Debra K. · CIK 0001772891 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,793 Underlying: Common Shares · 16,793 shares Expires 2026-07-11 F1 · price: The reported securities are included within 16,793 Issuer Units purchased by the Reporting Person for $1.50 per Unit. Each Unit consists of one common share, one Series A common warrant and one Series B common warrant, each warrant represents the right to purchase 16,793 shares of common stock. F3 · derivative.exercise_date: Fully vested and exercisable. Read SEC document |
| July 11, 2025 Filed Jul 15, 2025 20:15 UTC | Milestone Pharmaceuticals Inc. MIST · Entity 6561 | GrantCommon Shares | 16,666 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-019776 · form4-07152025_040723.xml · nonDerivative · entry 1 Liebert Debra K. · CIK 0001772891 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,793 F1 · price: The reported securities are included within 16,793 Issuer Units purchased by the Reporting Person for $1.50 per Unit. Each Unit consists of one common share, one Series A common warrant and one Series B common warrant, each warrant represents the right to purchase 16,793 shares of common stock. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 20:21 UTC | Milestone Pharmaceuticals Inc. MIST · Entity 6561 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $3.86 | $0.00 |
DisclosureSEC source: 0001209191-23-035838 · doc4.xml · derivative · entry 1 Liebert Debra K. · CIK 0001772891 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Shares · 30,000 shares Expires 2033-06-07 F1 · derivative.exercise_date: This option will vest in twelve (12) equal monthly installments, beginning on July 7, 2023, provided that the option will in any case be fully vested on the date of next annual meeting of the stockholders of the Issuer, subject to the Reporting Person continuing to provide service through each such vesting date. Read SEC document |
| October 21, 2022 Filed Oct 21, 2022 23:02 UTC | Milestone Pharmaceuticals Inc. MIST · Entity 6561 | PurchaseCommon Shares | 4,000 | $5.26 | $21,040.00 |
DisclosureSEC source: 0001209191-22-054326 · doc4.xml · nonDerivative · entry 2 Liebert Debra K. · CIK 0001772891 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By: Trust Disclosed balance after: 4,000 F2 · ownership.nature: These shares are held in a trust for the benefit of several including the Reporting Person's spouse. The Reporting Person's spouse is a co-executor of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| October 20, 2022 Filed Oct 21, 2022 23:02 UTC | Milestone Pharmaceuticals Inc. MIST · Entity 6561 | PurchaseCommon Shares | 10,000 | $5.29 | $52,900.00 |
DisclosureSEC source: 0001209191-22-054326 · doc4.xml · nonDerivative · entry 1 Liebert Debra K. · CIK 0001772891 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By: The Rodriguez and Liebert Revocable Trust Disclosed balance after: 10,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.24 to $5.30 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| September 14, 2022 Filed Sep 15, 2022 20:30 UTC | Milestone Pharmaceuticals Inc. MIST · Entity 6561 | OtherCommon Shares | 127 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-050075 · doc4.xml · nonDerivative · entry 1 Liebert Debra K. · CIK 0001772891 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127 F1 · kind: Represents a pro rata distribution without additional consideration to the Reporting Person from a limited liability company in which the Reporting Person is a member. Read SEC document |
| July 05, 2022 Filed Aug 11, 2022 22:00 UTC | Milestone Pharmaceuticals Inc. MIST · Entity 6561 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $6.07 | $0.00 |
DisclosureSEC source: 0001209191-22-045468 · doc4.xml · derivative · entry 1 Liebert Debra K. · CIK 0001772891 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Shares · 30,000 shares Expires 2032-07-05 F1 · derivative.exercise_date: This option will vest in twelve (12) equal monthly installments, beginning on August 5, 2022, provided that the option will in any case be fully vested on the date of next annual meeting of the stockholders of the Issuer, subject to the Reporting Person continuing to provide service through each such vesting date. Read SEC document |
| June 14, 2021 Filed Jul 29, 2021 21:37 UTC | Milestone Pharmaceuticals Inc. MIST · Entity 6561 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $5.54 | $0.00 |
DisclosureSEC source: 0001209191-21-048567 · doc4.xml · derivative · entry 1 Liebert Debra K. · CIK 0001772891 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Shares · 30,000 shares Expires 2031-06-14 F1 · derivative.exercise_date: This option will vest in twelve (12) equal monthly installments, beginning on July 14, 2021, provided that the option will in any case be fully vested on the date of next annual meeting of the stockholders of the Issuer, subject to the Reporting Person continuing to provide service through each such vesting date. Read SEC document |
| June 05, 2020 Filed Jun 8, 2020 23:04 UTC | Milestone Pharmaceuticals Inc. MIST · Entity 6561 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $3.74 | $0.00 |
DisclosureSEC source: 0001209191-20-035114 · doc4.xml · derivative · entry 1 Liebert Debra K. · CIK 0001772891 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Shares · 15,000 shares Expires 2030-06-05 F1 · derivative.exercise_date: The shares subject to this option shall vest in equal monthly installments over the 12 months commencing July 5, 2020, provided that the shares subject to this option shall vest in full on the date of Issuer's 2021 annual meeting of shareholders, subject to recipient continuing to provide service to the Issuer through such vesting date. Read SEC document |
| November 12, 2019 Filed Nov 14, 2019 23:40 UTC | Milestone Pharmaceuticals Inc. MIST · Entity 6561 | GrantStock Option (right to buy) · Derivative | 19,000 | $0.00 Strike: $17.78 | $0.00 |
DisclosureSEC source: 0001209191-19-056625 · doc4.xml · derivative · entry 1 Liebert Debra K. · CIK 0001772891 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Shares · 19,000 shares Expires 2029-11-12 F1 · derivative.exercise_date: This option will vest in equal monthly installments, beginning on December 12, 2019, over a period of three years, subject to the Reporting Person continuing to provide service through each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.